{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:23:12Z","timestamp":1790504592226,"version":"4.1.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.pupt.2017.03.009","type":"journal-article","created":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T18:17:40Z","timestamp":1489601860000},"page":"46-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Sorafenib as a potential strategy for refractory pulmonary arterial hypertension"],"prefix":"10.1016","volume":"44","author":[{"given":"Gou","family":"Kimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Inami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2017.03.009_bib1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.7326\/0003-4819-107-2-216","article-title":"Primary pulmonary hypertension: a national prospective study","volume":"107","author":"Rich","year":"1987","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.pupt.2017.03.009_bib2","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1161\/01.CIR.102.22.2781","article-title":"Primary pulmonary hypertension: a vascular biology and translational research \u201cwork in progress\u201d","volume":"102","author":"Archer","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pupt.2017.03.009_bib3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.pupt.2017.03.009_bib4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.pupt.2017.03.009_bib5","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1161\/CIRCULATIONAHA.108.779751","article-title":"Combined tyrosine and serine\/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling","volume":"118","author":"Klein","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pupt.2017.03.009_bib6","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1152\/physiolgenomics.00169.2007","article-title":"Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension","volume":"33","author":"Moreno-Vinasco","year":"2008","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.pupt.2017.03.009_bib7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/clpt.2009.217","article-title":"A\u00a0dosing\/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension","volume":"87","author":"Gomberg-Maitland","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pupt.2017.03.009_bib8","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa035115","article-title":"Expression of human herpesvirus 8 in primary pulmonary hypertension","volume":"349","author":"Cool","year":"2003","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"25 Suppl","key":"10.1016\/j.pupt.2017.03.009_bib9","doi-asserted-by":"crossref","first-page":"D82","DOI":"10.1016\/j.jacc.2013.10.026","article-title":"New trial designs and potential therapies for pulmonary artery hypertension","volume":"62","author":"Gomberg-Maitland","year":"2013","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.pupt.2017.03.009_bib10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/978-1-60761-500-2_27","article-title":"Receptor tyrosine kinase inhibitors in rodent pulmonary hypertension","volume":"661","author":"Moreno-Vinasco","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.pupt.2017.03.009_bib11","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1165\/rcmb.2010-0371OC","article-title":"Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats","volume":"45","author":"Abe","year":"2011","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"10.1016\/j.pupt.2017.03.009_bib12","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study","volume":"127","author":"Hoeper","year":"2013","journal-title":"Circulation"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553917300846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553917300846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T14:55:42Z","timestamp":1535986542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553917300846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":12,"alternative-id":["S1094553917300846"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2017.03.009","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sorafenib as a potential strategy for refractory pulmonary arterial hypertension","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2017.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}